Prognostic value of endothelial activation and stress index (EASIX) on short-term and long-term outcomes in type B aortic dissection after thoracic endovascular repair: An observational study Authors: Xiaosi Chen, Min Liu, Dongqin Cai, Yuan Liu, Nianjin Xie, Songyuan Luo, Jianfang Luo Published: 2026 ABSTRACT ObjectiveThe association between endothelial activation and stress index (EASIX) and both short-term and long-term outcomes in patients with type B aortic dissection (TBAD) undergoing thoracic endovascular repair (TEVAR) remains unclear. This study aimed to explore this relationship.MethodsWe conducted a retrospective analysis of 1090 patients with TBAD who underwent TEVAR. Patients were grouped into tertiles according to log2-transformed EASIX. Logistic and Cox regression, win ratio, landmark analysis, propensity score matching, and receiver operating characteristic analyses were performed to evaluate the prognostic and predictive value of EASIX for short-term and long-term outcomes.ResultsA total of 172 (15.8%) patients experienced short-term adverse events, and 206 (18.9%) patients died during a median follow-up of 7.04 years. Logistic regression analyses indicated that greater EASIX levels were associated with an increased risk of composite end points (odds ratio, 1.69; 95% CI, 1.37-2.08; P < .001), as well as new-onset dialysis, organ ischemia, and 30-day death. In multivariable Cox regression analyses, EASIX was identified as an independent predictor of all-cause mortality (hazard ratio, 1.43; 95% CI, 1.23-1.68; P < .001). The combined models incorporating EASIX demonstrated superior predictive performance for short-term outcomes compared with the baseline models (DeLong test P < .05). Time-dependent receiver operating characteristic analysis revealed greater combined model area under the curves than baseline model for all-cause mortality at 1-, 3-, 5-, and 10-year follow-up (likelihood ratio test P < .001).ConclusionsEASIX was associated with both short-term and long-term outcomes in patients with TBAD after TEVAR. Therefore, EASIX may serve as a supplementary indicator for risk stratification before intervention. Kaplan-Meier curves for long-term all-cause mortality. Central MessageEASIX is associated with both short-term and long-term outcomes in patients with TBAD after TEVAR. Adding EASIX to traditional prognostic factors can improve predictive performance. PerspectiveEndothelial cell dysfunction may be critical in AD prognosis. We found that higher EASIX was associated with increased risks of short-term adverse events and all-cause mortality in patients with TBAD after TEVAR. Adding EASIX to traditional factors can improve predictive performance. Thus, EASIX may be a supplementary indicator for risk stratification before intervention. See Commentary on page XXX. Kaplan-Meier curves for long-term all-cause mortality. Central Message EASIX is associated with both short-term and long-term outcomes in patients with TBAD after TEVAR. Adding EASIX to traditional prognostic factors can improve predictive performance. Perspective Endothelial cell dysfunction may be critical in AD prognosis. We found that higher EASIX was associated with increased risks of short-term adverse events and all-cause mortality in patients with TBAD after TEVAR. Adding EASIX to traditional factors can improve predictive performance. Thus, EASIX may be a supplementary indicator for risk stratification before intervention. See Commentary on page XXX. Type B aortic dissection (TBAD) is a potentially fatal condition associated with a high prevalence of complications. Current consensus indicates that, under favorable anatomical conditions, thoracic endovascular aortic repair (TEVAR) constitutes a valuable therapeutic strategy for patients with TBAD.1 However, the incidence of postoperative mortality and complications remains at a high level during short- and long-term follow-up.2 Consequently, early identification of patients at high risk for adverse events after TEVAR, along with optimized perioperative management, is essential for improving clinical outcomes. Aortic dissection (AD) is characterized by endothelial cell dysfunction, loss of vascular smooth muscle cells, and degradation of elastic fibers in the aortic wall. These alterations can lead to rupture and fatality. The endothelial cell dysfunction and tearing of the intima are critical steps in the development of AD.3,4 Although TEVAR addresses the acute entry tear, it introduces new challenges: stent graft implantation and altered hemodynamics (eg, from residual false lumen) impose sustained mechanical stress and a proinflammatory state that may exacerbate endothelial injury.5, 6, 7 Therefore, preserving endothelial integrity is critical not only for AD pathogenesis but also for recovery after TEVAR. However, endothelial dysfunction (ED) is rarely assessed clinically, underscoring the need for an accessible and objective index for risk stratification in TBAD. To quantify systemic endothelial impairment, the Endothelial Activation and Stress Index (EASIX)—a noninvasive quantitative biomarker derived from readily available serum measurements of creatinine, lactate dehydrogenase (LDH), and platelet (PLT) count—was initially developed to assess the severity of endotheliopathy in patients undergoing stem cell transplantation.8 The EASIX correlation has been elucidated with various endothelial activation markers: chemokine-X-C-ligand 8, interleukin-18, tumorigenicity-2 suppressor, and insulin-like growth factor-1.8,9 Subsequent studies have extended its clinical relevance to systemic conditions such as sepsis10 and stroke.11 More importantly, accumulating evidence has highlighted its prognostic value in cardiovascular diseases, where ED plays a central role. In this context, EASIX has been associated with adverse outcomes in patients with coronary artery disease (CAD),12 acute myocardial infarction,13 hypertension,14 and aortic stenosis patients undergoing transcatheter aortic valve replacement.15 The association between EASIX and the prognosis of patients with TBAD after TEVAR has yet to be explored. To address this gap, this study evaluated the value of EASIX in predicting early and late adverse outcomes. Methods Patient Population This was a single-center study conducted at Guangdong Provincial People's Hospital. Patients with acute and subacute TBAD undergoing TEVAR were consecutively enrolled from January 2010 to January 2024. TBAD was diagnosed using multidetector computed tomography scanning. The exclusion criteria were as follows: (1) chronic TBAD with symptom onset-to-treatment duration >3 months; (2) Marfan syndrome; (3) malignant tumors; (4) autoimmune diseases; (5) history of endovascular procedures; and (6) missing key blood parameters. After we applied these criteria, the final cohort included 1090 patients (Figure 1). The study was approved by the Institutional Ethics Committee of our hospital (date of review: March 29, 2023; approval no. 2019-328H-2), which granted a waiver for informed consent because of the retrospective study design.Figure 1Patient flow chart of study enrollment. History of endovascular implant procedures: percutaneous coronary intervention, coronary artery bypass grafting, TEVAR/EVAR, aortic replacement, or valve replacement. TBAD, Type B aortic dissection; TEVAR, thoracic endovascular aortic repair; EVAR, endovascular aneurysm repair. Patient flow chart of study enrollment. History of endovascular implant procedures: percutaneous coronary intervention, coronary artery bypass grafting, TEVAR/EVAR, aortic replacement, or valve replacement. TBAD, Type B aortic dissection; TEVAR, thoracic endovascular aortic repair; EVAR, endovascular aneurysm repair. Data Collection and Definitions Demographics, medical history, comorbidities, laboratory findings, imaging characteristics, and follow-up details were retrospectively recorded and analyzed by 2 researchers. The complete blood count was collected at the time of admission and before TEVAR and measured with an automated blood cell counter (XE-5000; Sysmex). The EASIX parameters, along with the other laboratory values, were obtained from the same blood draw. The EASIX was calculated on the basis of the following formula: LDH (U/L) × creatinine (mg/dL)/PLT (109 cells/L) and log2 conversion for statistical analysis (all EASIX shown in this article are log2 transformed).8 According to EASIX tertiles, the participants were divided into 3 distinct groups: T1 (n = 364, EASIX <0.743), T2 (n = 363, 0.743 < EASIX <1.162), and T3 (n = 363, 1.162 < EASIX). “Acute” TBAD is defined as a condition lasting for <2 weeks, “subacute” as that lasting for 2 weeks to 3 months, and “chronic” as that lasting for >3 months from symptom onset. Complicated TBAD is characterized by dissection with malperfusion of the spinal cord, gastrointestinal tract, the kidneys, or extremities; pleural effusion containing blood, contained or free aortic rupture, persistent pain, and uncontrollable arterial hypertension.16 Malperfusion was defined as inadequate blood flow to the end organs as a result of dissection-related obstruction of the aorta and/or its branches. TEVAR Indication and Brief Procedure All patients received optimal medications and underwent TEVAR, as recommended by the guidelines hypertension.16 TEVAR was recommended for patients with complicated TBAD. For those with uncomplicated TBAD, TEVAR was considered if any of the following criteria were met: primary entry >10 mm, primary entry at the inner curvature, primary entry located <20 mm to the subclavian artery, false lumen diameter >22 mm, or descending thoracic aortic diameter >40 mm. TEVAR was performed by a multidisciplinary team comprising interventional cardiologists, cardiothoracic surgeons, anesthetists, and intensivists. For patients with proximal landing zones 1 and 2 or an aberrant right subclavian artery, depending on individualized treatment, a chimney stent or aortic arch bypass was added to TEVAR. The proximal landing zone had to be 2 cm in length, and the device at least 15 cm long. The final decision on TEVAR was a consensus reached with the full informed consent of the patients and family. More procedure details regarding the extent of coverage, oversize rate, type of devices, and endoleak management were provided in the supplementary materials. Clinical Outcomes Follow-up was performed either by scheduled ambulatory visits or telephone interviews. Our clinical focus is divided into short-term and long-term outcomes. Short-term outcomes were assessed using a composite end point of adverse events after TEVAR, defined as 30-day death or any in-hospital complication, including cerebral infarction, spinal cord ischemia (SCI), organ ischemia, limb ischemia, new-onset dialysis, delirium, and reoperation. The composite end point was considered met upon the occurrence of any single event. Individual events were also analyzed as separate outcomes. Long-term outcome refers to all-cause mortality during follow-up, which commenced on the date of the TEVAR procedure and continued until the occurrence of all-cause death or the study cutoff date (February 1, 2025). For a patient developing multiple outcomes during hospitalization, only one outcome was recorded. Statistical Analyses Continuous variables are presented as means ± SDs for normally distributed data or as medians (interquartile ranges [IQRs]) for non-normally distributed data. Categorical variables are reported as frequencies and percentages. Differences in continuous or categorical variables between groups were assessed using χ2 tests, one-way analysis of variance, or Kruskal-Wallis tests, as appropriate. Logistic and Cox regression analyses were performed to identify independent predictors of short-term and long-term outcomes. Variables with P < .1 in the univariate analysis were included in the multivariate analysis. The P values for multiple outcomes (excluding composite end point) in logistic regression analyses were adjusted for multiplicity using the Benjamini-Hochberg correction at a false discovery rate (FDR) of 0.05. Short-term adverse events were evaluated using the win ratio method to account for their non-equivalent clinical severity (see Appendix E1). Kaplan-Meier curves were used to estimate the cumulative mortality rate, and the log-rank test was applied to compare differences among the 3 groups. Landmark analysis evaluated temporal changes in long-term mortality risk profiles. Receiver operating characteristic (ROC) analysis was conducted to evaluate the predictive value of EASIX for short-term adverse events. The DeLong test was used to compare the area under the curve (AUC) between different models. Time-dependent ROC analysis assessed the predictive value of EASIX for all-cause mortality. Model comparisons were performed using the likelihood ratio test. Using variables with P < .05 from the multivariate analysis results, a baseline model was constructed (details of variables included in the baseline model are provided in Table E1). On the basis of baseline model, EASIX was incorporated to form the combined model. Statistical analyses were conducted using R software, version 4.5.0. Sensitivity Analysis To address potential selection bias, 1:1 propensity-score matching was performed using the nearest-neighbor algorithm without replacement. Covariates included in the matching model were age, sex, hypertension, CAD, chronic kidney disease (CKD), maximal aortic diameter (MAD), complications, AD stage, and procedures. Postmatching balance between groups was evaluated using the standardized mean difference, with standardized mean difference <0.20 indicating adequate balance. Furthermore, to address potential residual confounding, multivariable stratified analyses were performed. Patients were stratified by age, sex, CKD, creatinine levels, complicated TBAD, AD stage, MAD, and procedure. These models were adjusted for the aforementioned covariates (excluding the specific stratification variable being analyzed to prevent collinearity). Finally, interaction tests were conducted to determine whether the prognostic value of the EASIX score was modified by these clinical subgroups. Results Baseline Characteristics of the Participants Baseline characteristics according to the EASIX tertiles are presented in Table 1. A total of 1090 patients with TBAD who underwent TEVAR were analyzed. The mean age of the participants was 54 years, with 87.3% male and 12.7% female. The most common comorbid condition was hypertension (82.5%), followed by CAD (13.6%), CKD (8.9%), hyperlipidemia (8.5%), and diabetes (6.1%). The mean MAD was 37.3 mm, and the mean EASIX level was 0.9. Among the patients, 537 (49.3%) had complicated TBAD and 876 (80.4%) were in the acute phase at the time of TEVAR.Table 1Baseline characteristics of TBAD patients grouped by EASIX tertilesVariablesTotalT1T2T3P valueAge, y54.0 (46.00-63.0)54.5 (45.8-62.0)54.0 (46.0-62.0)55.0 (47.0-65.0).319Sex<.001 Male952 (87.3%)288 (79.1%)331 (91.2%)333 (91.7%) Female138 (12.7%)76 (20.9%)32 (8.8%)30 (8.3%)Smoking522 (47.9%)169 (46.4%)189 (52.1%)164 (45.2%).141Comorbidities Hypertension899 (82.5%)280 (76.9%)302 (83.2%)317 (87.3%).001 CAD148 (13.6%)43 (11.8%)49 (13.5%)56 (15.4%).363 Diabetes66 (6.1%)22 (6.0%)25 (6.9%)19 (5.2%).647 Hyperlipidemia93 (8.5%)25 (6.9%)29 (8.0%)39 (10.7%).157 CKD97 (8.9%)10 (2.7%)22 (6.1%)65 (17.9%)<.001Laboratory tests WBCs, 109/L10.4 (8.31-12.8)9.5 (7.8-11.6)10.6 (8.2-12.9)11.5 (8.9-14.0)<.001 RBCs, 109/L4.4 (4.00-4.8)4.3 (4.0-4.7)4.5 (4.1-4.9)4.4 (3.9-4.9).016 PLT, 109/L207.0 (165.03-277.0)287.5 (226.8-360.6)197.7 (169.5-232.5)164.0 (138.0-203.4)<.001 DDI, μg/mL2430.0 (1042.50-4280.0)1865.0 (677.0-3120.0)2200.0 (1035.0-3865.0)3360.0 (1765.0-9715.0)<.001 ALT, U/L21.9 (15.00-35.0)22.0 (15.0-36.0)21.0 (14.0-32.0)22.0 (15.0-40.5).040 AST, U/L21.5 (17.00-30.0)20.8 (16.0-28.0)21.0 (17.0-28.0)24.0 (18.0-38.5)<.001 ALB, g/L34.4 (30.71-37.5)34.2 (30.4-37.0)35.3 (31.8-38.3)33.5 (30.1-36.9)<.001 LDH, U/L184.0 (153.00-227.8)156.5 (137.8-186.0)178.0 (155.0-200.2)234.0 (194.0-326.0)<.001 Total cholesterol, mg/dL4.4 (3.66-5.1)4.3 (3.7-4.9)4.4 (3.6-5.1)4.5 (3.7-5.1).280 Triglycerides, mg/dL1.2 (0.96-1.7)1.2 (0.9-1.6)1.2 (0.9-1.7)1.3 (1.0-1.8).039 LDL-C, mg/dL2.7 (2.16-3.2)2.8 (2.2-3.2)2.7 (2.1-3.2)2.7 (2.1-3.2).415 HDL-C, mg/dL1.0 (0.78-1.1)0.9 (0.7-1.1)1.0 (0.8-1.2)1.0 (0.8-1.2)<.001 BUN, mg/dL5.9 (4.54-7.8)5.0 (3.9-6.3)5.9 (4.6-7.2)7.5 (5.6-10.8)<.001 Creatinine, μmol/L89.8 (73.62-118.0)73.5 (62.1-86.0)89.2 (77.0-104.0)123.0 (95.9-173.2)<.001 Complicated TBAD537 (49.3%)142 (39.0%)186 (51.2%)209 (57.6%)<.001 Acute TBAD876 (80.4%)252 (69.2%)298 (82.1%)326 (89.8%)<.001 MAD, mm37.3 (34.00-42.2)37.0 (33.3-42.0)38.0 (34.2-43.0)38.0 (34.0-42.8).156 EASIX0.9 (0.65-1.3)0.6 (0.5-0.7)0.9 (0.8-1.0)1.5 (1.3-2.2)<.001Operative procedure.157 TEVAR693 (63.6%)249 (68.4%)218 (60.1%)226 (62.3%) TEVAR with aortic arch bypass302 (27.7%)88 (24.2%)113 (31.1%)101 (27.8%) TEVAR with chimney stent95 (8.7%)27 (7.4%)32 (8.8%)36 (9.9%)Surgery period.157 Period 1364 (33.4%)133 (36.5%)125 (34.4%)106 (29.2%) Period 2363 (33.3%)109 (29.9%)117 (32.2%)137 (37.7%) Period 3363 (33.3%)122 (33.5%)121 (33.3%)120 (33.1%)Short-term outcomes Composite end point172 (15.8%)36 (9.9%)40 (11.0%)96 (26.4%)<.001 30-d death19 (1.7%)3 (0.8%)4 (1.1%)12 (3.3%).02 Cerebral infarction28 (2.6%)6 (1.6%)2 (0.6%)20 (5.5%)<.001 SCI19 (1.7%)4 (1.1%)4 (1.1%)11 (3.0%).072 Limb ischemia35 (3.2%)8 (2.2%)11 (3.0%)16 (4.4%).233 Organ ischemia15 (1.4%)3 (0.8%)2 (0.6%)10 (2.8%).025 New-onset dialysis28 (2.6%)1 (0.3%)5 (1.4%)22 (6.1%)<.001 Delirium79 (7.2%)14 (3.8%)17 (4.7%)48 (13.2%)<.001 Reoperation12 (1.1%)2 (0.5%)5 (1.4%)5 (1.4%).446T1: EASIX's first tertile group; T2: EASIX's second tertile group; T3: EASIX's third tertile group. The cohort was divided into 3 equal time intervals on the basis of surgery date: period 1 (January 11, 2010, to November 14, 2013), period 2 (November 15, 2013, to February 13, 2018), and period 3 (February 14, 2018, to June 1, 2024). TBAD, Type B aortic dissection; EASIX, endothelial activation and stress index; CAD, coronary artery disease; CKD, chronic kidney disease; WBC, white blood cell; RBC, red blood cells; PLT, platelet; DDI, d-dimer index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; LDH, lactate dehydrogenase; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BUN, blood urea nitrogen; MAD, maximal aortic diameter; TEVAR, thoracic endovascular repair. Table 1Baseline characteristics of TBAD patients grouped by EASIX tertilesVariablesTotalT1T2T3P valueAge, y54.0 (46.00-63.0)54.5 (45.8-62.0)54.0 (46.0-62.0)55.0 (47.0-65.0).319Sex<.001 Male952 (87.3%)288 (79.1%)331 (91.2%)333 (91.7%) Female138 (12.7%)76 (20.9%)32 (8.8%)30 (8.3%)Smoking522 (47.9%)169 (46.4%)189 (52.1%)164 (45.2%).141Comorbidities Hypertension899 (82.5%)280 (76.9%)302 (83.2%)317 (87.3%).001 CAD148 (13.6%)43 (11.8%)49 (13.5%)56 (15.4%).363 Diabetes66 (6.1%)22 (6.0%)25 (6.9%)19 (5.2%).647 Hyperlipidemia93 (8.5%)25 (6.9%)29 (8.0%)39 (10.7%).157 CKD97 (8.9%)10 (2.7%)22 (6.1%)65 (17.9%)<.001Laboratory tests WBCs, 109/L10.4 (8.31-12.8)9.5 (7.8-11.6)10.6 (8.2-12.9)11.5 (8.9-14.0)<.001 RBCs, 109/L4.4 (4.00-4.8)4.3 (4.0-4.7)4.5 (4.1-4.9)4.4 (3.9-4.9).016 PLT, 109/L207.0 (165.03-277.0)287.5 (226.8-360.6)197.7 (169.5-232.5)164.0 (138.0-203.4)<.001 DDI, μg/mL2430.0 (1042.50-4280.0)1865.0 (677.0-3120.0)2200.0 (1035.0-3865.0)3360.0 (1765.0-9715.0)<.001 ALT, U/L21.9 (15.00-35.0)22.0 (15.0-36.0)21.0 (14.0-32.0)22.0 (15.0-40.5).040 AST, U/L21.5 (17.00-30.0)20.8 (16.0-28.0)21.0 (17.0-28.0)24.0 (18.0-38.5)<.001 ALB, g/L34.4 (30.71-37.5)34.2 (30.4-37.0)35.3 (31.8-38.3)33.5 (30.1-36.9)<.001 LDH, U/L184.0 (153.00-227.8)156.5 (137.8-186.0)178.0 (155.0-200.2)234.0 (194.0-326.0)<.001 Total cholesterol, mg/dL4.4 (3.66-5.1)4.3 (3.7-4.9)4.4 (3.6-5.1)4.5 (3.7-5.1).280 Triglycerides, mg/dL1.2 (0.96-1.7)1.2 (0.9-1.6)1.2 (0.9-1.7)1.3 (1.0-1.8).039 LDL-C, mg/dL2.7 (2.16-3.2)2.8 (2.2-3.2)2.7 (2.1-3.2)2.7 (2.1-3.2).415 HDL-C, mg/dL1.0 (0.78-1.1)0.9 (0.7-1.1)1.0 (0.8-1.2)1.0 (0.8-1.2)<.001 BUN, mg/dL5.9 (4.54-7.8)5.0 (3.9-6.3)5.9 (4.6-7.2)7.5 (5.6-10.8)<.001 Creatinine, μmol/L89.8 (73.62-118.0)73.5 (62.1-86.0)89.2 (77.0-104.0)123.0 (95.9-173.2)<.001 Complicated TBAD537 (49.3%)142 (39.0%)186 (51.2%)209 (57.6%)<.001 Acute TBAD876 (80.4%)252 (69.2%)298 (82.1%)326 (89.8%)<.001 MAD, mm37.3 (34.00-42.2)37.0 (33.3-42.0)38.0 (34.2-43.0)38.0 (34.0-42.8).156 EASIX0.9 (0.65-1.3)0.6 (0.5-0.7)0.9 (0.8-1.0)1.5 (1.3-2.2)<.001Operative procedure.157 TEVAR693 (63.6%)249 (68.4%)218 (60.1%)226 (62.3%) TEVAR with aortic arch bypass302 (27.7%)88 (24.2%)113 (31.1%)101 (27.8%) TEVAR with chimney stent95 (8.7%)27 (7.4%)32 (8.8%)36 (9.9%)Surgery period.157 Period 1364 (33.4%)133 (36.5%)125 (34.4%)106 (29.2%) Period 2363 (33.3%)109 (29.9%)117 (32.2%)137 (37.7%) Period 3363 (33.3%)122 (33.5%)121 (33.3%)120 (33.1%)Short-term outcomes Composite end point172 (15.8%)36 (9.9%)40 (11.0%)96 (26.4%)<.001 30-d death19 (1.7%)3 (0.8%)4 (1.1%)12 (3.3%).02 Cerebral infarction28 (2.6%)6 (1.6%)2 (0.6%)20 (5.5%)<.001 SCI19 (1.7%)4 (1.1%)4 (1.1%)11 (3.0%).072 Limb ischemia35 (3.2%)8 (2.2%)11 (3.0%)16 (4.4%).233 Organ ischemia15 (1.4%)3 (0.8%)2 (0.6%)10 (2.8%).025 New-onset dialysis28 (2.6%)1 (0.3%)5 (1.4%)22 (6.1%)<.001 Delirium79 (7.2%)14 (3.8%)17 (4.7%)48 (13.2%)<.001 Reoperation12 (1.1%)2 (0.5%)5 (1.4%)5 (1.4%).446T1: EASIX's first tertile group; T2: EASIX's second tertile group; T3: EASIX's third tertile group. The cohort was divided into 3 equal time intervals on the basis of surgery date: period 1 (January 11, 2010, to November 14, 2013), period 2 (November 15, 2013, to February 13, 2018), and period 3 (February 14, 2018, to June 1, 2024). TBAD, Type B aortic dissection; EASIX, endothelial activation and stress index; CAD, coronary artery disease; CKD, chronic kidney disease; WBC, white blood cell; RBC, red blood cells; PLT, platelet; DDI, d-dimer index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; LDH, lactate dehydrogenase; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BUN, blood urea nitrogen; MAD, maximal aortic diameter; TEVAR, thoracic endovascular repair. Baseline characteristics of TBAD patients grouped by EASIX tertiles T1: EASIX's first tertile group; T2: EASIX's second tertile group; T3: EASIX's third tertile group. The cohort was divided into 3 equal time intervals on the basis of surgery date: period 1 (January 11, 2010, to November 14, 2013), period 2 (November 15, 2013, to February 13, 2018), and period 3 (February 14, 2018, to June 1, 2024). TBAD, Type B aortic dissection; EASIX, endothelial activation and stress index; CAD, coronary artery disease; CKD, chronic kidney disease; WBC, white blood cell; RBC, red blood cells; PLT, platelet; DDI, d-dimer index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; LDH, lactate dehydrogenase; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BUN, blood urea nitrogen; MAD, maximal aortic diameter; TEVAR, thoracic endovascular repair. There were significant differences observed in sex, hypertension, CKD, and whether the TBAD was complicated or in the acute phase at the time of TEVAR. However, there were no differences in age, smoking status, CAD, diabetes, hyperlipidemia, or MAD. Individual EASIX components (LDH, creatinine, and platelets) exhibited a distinct gradient distribution across the 3 tertiles (P < .001). In addition, patients in the T3 group had greater levels of white blood cells (WBC), D-dimer index, aspartate aminotransferase, and blood urea nitrogen but lower albumin levels (P < .05). Regarding lipid profiles, no significant differences were observed among the 3 groups in total cholesterol or low-density lipoprotein cholesterol levels (P > .05), though slightly elevated triglycerides (P = .039) and greater high-density lipoprotein cholesterol levels (P < .001) were noted in the T3 group. Furthermore, Table 1 details the adverse events across the EASIX tertiles. Among the 1090 patients, 172 (15.8%) experienced the composite end point. Specifically, 19 patients died within 30 days after TEVAR, 28 developed cerebral infarction, 19 had SCI, 35 had limb ischemia, 15 had organ ischemia, 28 required new-onset dialysis, 79 experienced delirium, and 12 underwent reoperation. Greater EASIX levels were significantly associated with increased rates of the composite end point (P < .001), 30-day death (P = .02), cerebral infarction (P < .001), organ ischemia (P = .025), new-onset dialysis (P < .001), and delirium (P < .001). Although the differences in other complications—including SCI, limb ischemia, and reoperation—did not reach statistical significance (all P > .05), a numerical increase in their incidence was observed with greater EASIX levels. Short-Term Adverse Events The association between the EASIX and short-term adverse events was evaluated using multivariable logistic regression models (Table 2, the results of the full model covariates are shown in Table E2). After we adjusted for covariates, a greater EASIX score was independently associated with an increased risk of the composite end point (odds ratio [OR], 1.69; 95% CI, 1.37-2.08, P < .001). Furthermore, after adjusting for multiple testing, EASIX remained significantly associated with new-onset dialysis (OR, 2.28; 95% CI, 1.64-3.17, FDR-adjusted P < .001), organ ischemia (OR, 1.89; 95% CI, 1.31-2.71, FDR-adjusted P = .002), and 30-day death (OR, 1.56; 95% CI, 1.08-2.25, FDR-adjusted P = .048). Conversely, EASIX was not significantly associated with delirium, SCI, limb ischemia, cerebral infarction, or reoperation (all FDR-adjusted P > .05). The win ratio for the short-term adverse events was 2.76 (95% CI, 1.72-4.45, P < .001) (Figure E1).Table 2Multivariate logistic regression analysis of EASIX and short-term adverse eventsOutcomesOR (95% CI)P valueFDR-adjusted PSignificant FDRComposite end point1.69 (1.37-2.08)<.001––New-onset dialysis2.28 (1.64-3.17)<.001<0.001YesOrgan ischemia1.89 (1.31-2.71)<.0010.002Yes30-d death1.56 (1.08-2.25).0180.048YesDelirium1.23 (0.96-1.58).0950.152NoSpinal cord ischemia1.38 (0.93-2.03).1070.171NoLimb ischemia1.29 (0.92-1.80).1350.181NoReoperation1.22 (0.71-2.11).4750.522NoCerebral infarction1.14 (0.77-1.68).5220.522NoEASIX, Endothelial activation and stress index; OR, odds ratio; FDR, false discovery rate. Table 2Multivariate logistic regression analysis of EASIX and short-term adverse eventsOutcomesOR (95% CI)P valueFDR-adjusted PSignificant FDRComposite end point1.69 (1.37-2.08)<.001––New-onset dialysis2.28 (1.64-3.17)<.001<0.001YesOrgan ischemia1.89 (1.31-2.71)<.0010.002Yes30-d death1.56 (1.08-2.25).0180.048YesDelirium1.23 (0.96-1.58).0950.152NoSpinal cord ischemia1.38 (0.93-2.03).1070.171NoLimb ischemia1.29 (0.92-1.80).1350.181NoReoperation1.22 (0.71-2.11).4750.522NoCerebral infarction1.14 (0.77-1.68).5220.522NoEASIX, Endothelial activation and stress index; OR, odds ratio; FDR, false discovery rate. Multivariate logistic regression analysis of EASIX and short-term adverse events EASIX, Endothelial activation and stress index; OR, odds ratio; FDR, false discovery rate. Figure 2, A-D, demonstrates the predictive performance of EASIX for early adverse events. ROC analysis was performed to compare the baseline model with a combined model comprising EASIX and baseline predictors. Compared with the baseline model, the combined model demonstrated superior AUC performance across 4 early outcomes. The DeLong test results indicated statistically significant differences between the 2 models for the composite end point (P = .008), new-onset dialysis (P = .011), and 30-day death (P = .025) (Table E3). These findings indicated that incorporating EASIX into traditional predictors significantly enhanced predictive performance. Detailed analyses, including AUC improvements, sensitivity, and specificity, are presented in Table E1.Figure 2Receiver operating characteristic (ROC) analyses of 2 models for predicting short-term adverse events and all-cause mortality. A-D, ROC curves for short-term adverse events, including composite end point (A), new-onset dialysis (B), organ ischemia (C), and 30-day death (D). The baseline model for the composite end point included complicated TBAD, MAD, and WBC; for new-onset dialysis included WBC and RBC; for organ ischemia included DDI and WBCs; and for 30-day death included complicated TBAD. E, Time-dependent ROC curves for predicting all-cause mortality. The baseline model was constructed using age, MAD, WBC, and RBCs. F, Comparison of AUC values between the baseline and combined models at 1-, 3-, 5-, and 10-year follow-up. In all analyses, the combined models were established by adding EASIX to the respective baseline models. TBAD, Type B aortic dissection; MAD, maximum aortic diameter; WBC, white blood cell; RBC, red blood cell; AUC, area under the curve; TPR, true-positive rate; FPR, false-positive rate; LR, likelihood ratio. Receiver operating characteristic (ROC) analyses of 2 models for predicting short-term adverse events and all-cause mortality. A-D, ROC curves for short-term adverse events, including composite end point (A), new-onset dialysis (B), organ ischemia (C), and 30-day death (D). The baseline model for the composite end point included complicated TBAD, MAD, and WBC; for new-onset dialysis included WBC and RBC; for organ ischemia included DDI and WBCs; and for 30-day death included complicated TBAD. E, Time-dependent ROC curves for predicting all-cause mortality. The baseline model was constructed using age, MAD, WBC, and RBCs. F, Comparison of AUC values between the baseline and combined models at 1-, 3-, 5-, and 10-year follow-up. In all analyses, the combined models were established by adding EASIX to the respective baseline models. TBAD, Type B aortic dissection; MAD, maximum aortic diameter; WBC, white blood cell; RBC, red blood cell; AUC, area under the curve; TPR, true-positive rate; FPR, false-positive rate; LR, likelihood ratio. Long-Term Mortality During a median follow-up of 7.04 years (IQR, 4.51-10.77), 206 (18.9%) patients experienced all-cause mortality. The Kaplan-Meier survival analysis curves were used to evaluate the incidence of long-term all-cause mortality among various groups on the basis of tertile groupings of EASIX. Compared with the T1 and T2 groups, EASIX in the T3 group has a significantly greater cumulative incidence of all-cause mortality (P for log-rank test = .001, Figure 3). The results of the Cox regression analysis for the risk of all-cause death in patients with TBAD are presented in Table 3. EASIX, age, CAD, CKD, MAD, WBC, RBC, albumin, and high-density lipoprotein cholesterol showed significance in univariate analysis (P < .05). These variables were included in the multivariate Cox regression analysis. The results showed that EASIX was independently associated with greater all-cause mortality (hazard ratio, 1.43; 95% CI, 1.23-1.68, P < .001). In addition, age, MAD, WBC, and RBC were also independently associated with elevated all-cause mortality risk (P < .05). Furthermore, a 90-day landmark analysis confirmed that a greater EASIX score remained independently associated with increased risk of all-cause mortality (Table E4, Figure E2).Figure 3Kaplan-Meier curves for long-term all-cause mortality. T1: EASIX's first tertile group; T2: EASIX's second tertile group; T3: EASIX's third tertile group; The shaded areas represent the 95% CIs. EASIX, Endothelial activation and stress index.Table 3Univariate and multivariate Cox regression analysis of EASIX and all-cause mortalityVariablesUnivariate predictorsMultivariate predictorsHR (95% CI)P valueHR (95% CI)P valueEASIX1.34 (1.17-1.54)<.0011.43 (1.23-1.68)<.001Age1.05 (1.04-1.06)<.0011.04 (1.03-1.06)<.001CAD1.87 (1.35-2.58)<.0011.23 (0.88-1.73).234CKD1.71 (1.16-2.52).0071.47 (0.98-2.20).066MAD1.03 (1.02-1.04)<.0011.02 (1.001-1.03).041WBCs0.93 (0.90-1.97).0010.95 (0.91-0.99).015RBCs0.58 (0.47-0.71)<.0010.78 (0.63-0.97).023ALB0.95 (0.92-0.97)<.0010.99 (0.96-1.02).407HDL-C0.52 (0.32-0.86).0100.60 (0.35-1.00).052Model fit statistics for the multivariable analysis: C-index = 0.696; Likelihood ratio test P < .001. EASIX, Endothelial activation and stress index; HR, hazard ratio; CAD, coronary artery disease; CKD, chronic kidney disease; MAD, maximal aortic diameter; WBC, white blood cell; RBC, red blood cell; ALB, albumin; HDL-C, high-density lipoprotein cholesterol. Kaplan-Meier curves for long-term all-cause mortality. T1: EASIX's first tertile group; T2: EASIX's second tertile group; T3: EASIX's third tertile group; The shaded areas represent the 95% CIs. EASIX, Endothelial activation and stress index. Table 3Univariate and multivariate Cox regression analysis of EASIX and all-cause mortalityVariablesUnivariate predictorsMultivariate predictorsHR (95% CI)P valueHR (95% CI)P valueEASIX1.34 (1.17-1.54)<.0011.43 (1.23-1.68)<.001Age1.05 (1.04-1.06)<.0011.04 (1.03-1.06)<.001CAD1.87 (1.35-2.58)<.0011.23 (0.88-1.73).234CKD1.71 (1.16-2.52).0071.47 (0.98-2.20).066MAD1.03 (1.02-1.04)<.0011.02 (1.001-1.03).041WBCs0.93 (0.90-1.97).0010.95 (0.91-0.99).015RBCs0.58 (0.47-0.71)<.0010.78 (0.63-0.97).023ALB0.95 (0.92-0.97)<.0010.99 (0.96-1.02).407HDL-C0.52 (0.32-0.86).0100.60 (0.35-1.00).052Model fit statistics for the multivariable analysis: C-index = 0.696; Likelihood ratio test P < .001. EASIX, Endothelial activation and stress index; HR, hazard ratio; CAD, coronary artery disease; CKD, chronic kidney disease; MAD, maximal aortic diameter; WBC, white blood cell; RBC, red blood cell; ALB, albumin; HDL-C, high-density lipoprotein cholesterol. Univariate and multivariate Cox regression analysis of EASIX and all-cause mortality Model fit statistics for the multivariable analysis: C-index = 0.696; Likelihood ratio test P < .001. EASIX, Endothelial activation and stress index; HR, hazard ratio; CAD, coronary artery disease; CKD, chronic kidney disease; MAD, maximal aortic diameter; WBC, white blood cell; RBC, red blood cell; ALB, albumin; HDL-C, high-density lipoprotein cholesterol. Time-dependent ROC analysis was conducted to evaluate the prognostic value of the EASIX for all-cause mortality. The baseline model was constructed using age, MAD, WBC, and RBC, whereas the combined model incorporated EASIX as an additional factor alongside the baseline model. Compared with the baseline model, the combined model demonstrated improved predictive performance at 1 year (0.571 vs 0.615), 3 years (0.650 vs 0.685), 5 years (0.674 vs 0.703), and 10 years (0.685 vs 0.717), as shown in Figure 2, E. The likelihood ratio test confirmed that the addition of EASIX significantly improved the model fit (χ2 = 20.24, P < .001) (Figure 2, F). These results suggested that incorporating EASIX into traditional predictive biomarkers appears to enhance predictive value for long-term mortality. Sensitivity Analysis After 1:1 propensity-score matching, 322 patients were included in each group. The baseline characteristics after matching are presented in Table E5. Both Conditional logistic regression and stratified Cox proportional hazards models indicated that the greater-risk EASIX group was significantly associated with a greater risk of short-term and long-term outcomes (Table E6). Compared with the low EASIX group, the high EASIX group had a lower all-cause mortality rate (log-rank P = .009, Figure E3). Furthermore, multivariable stratified analyses confirmed the robustness of the EASIX score as an independent prognosticator (Figure 4, Figure E4). After adjusting for potential confounders within each stratum, the high EASIX group was associated with an increased risk of both short-term adverse events (ORs >1.0) and all-cause mortality (hazard ratio >1.0) across the majority of clinical subgroups. Notably, this significant association persisted even in lower-risk subsets, such as patients without CKD, baseline normal creatinine, and without complicated TBAD. In addition, the interaction tests for most subgroups were not statistically significant (P for interaction >.05), indicating that the predictive value of the EASIX score was stable.Figure 4Multivariate stratified analysis of short-term adverse events and all-cause mortality. Short-term adverse events included composite end point, new-onset dialysis, organ ischemia, and 30-day death. Interaction terms were tested using likelihood ratio tests. Stratified variables with fewer than 5 events did not displayed. OR, Odds ratio; CKD, chronic kidney disease; CREA, creatinine; TBAD, type B aortic dissection; TEVAR, thoracic endovascular aortic repair; MAD, maximum aortic diameter; HR, hazard ratio. Multivariate stratified analysis of short-term adverse events and all-cause mortality. Short-term adverse events included composite end point, new-onset dialysis, organ ischemia, and 30-day death. Interaction terms were tested using likelihood ratio tests. Stratified variables with fewer than 5 events did not displayed. OR, Odds ratio; CKD, chronic kidney disease; CREA, creatinine; TBAD, type B aortic dissection; TEVAR, thoracic endovascular aortic repair; MAD, maximum aortic diameter; HR, hazard ratio. Postoperative EASIX Variation and Prognosis Performance In this retrospective analysis, 587 patients had complete data for postoperative EASIX calculation (Table E7). No significant difference was observed between preoperative and postoperative EASIX levels (P = .663). Postoperative EASIX increased significantly across preoperative EASIX tertiles (T1 vs T2 vs T3, P < .001). These findings indicate a clear gradient relationship, with higher preoperative EASIX associated with greater postoperative EASIX. Multivariable analyses demonstrated that greater postoperative EASIX was independently associated with the composite end point, 30-day death, new-onset dialysis, organ ischemia, and all-cause mortality (P < .001) (Figure E5). Discussion This study identified a significant, independent inverse association between EASIX and short-term and long-term outcomes in patients with TBAD after TEVAR. When EASIX was added to traditional prognostic factors, predictive performance significantly improved. Therefore, EASIX could be considered a useful and relatively simple tool for pre-TEVAR risk stratification and management decisions. ED is a pivotal driver of aortic wall degradation and intimal tearing. Mechanistically, ED promotes atherosclerosis via inflammatory cell recruitment and matrix degradation17 and exacerbates hypertension through impaired nitric oxide bioavailability and increased endothelin-1.18 Given that both atherosclerosis and hypertension are well-known risk factors for TBAD, pre-existing ED—as reflected by high EASIX scores—can be used to identify patients at an elevated risk for poor prognosis. Importantly, ED not only triggers the initial TBAD development but also critically limits vascular recovery post-TEVAR. On one hand, anatomical characteristics like a residual false lumen cause incomplete thrombosis and aberrant hemodynamics (eg, oscillatory shear stress), continuously impairing endothelial integrity.6,7 On the other hand, the stent graft itself acts as a foreign body stimulus, independently prolonging vascular inflammation and endothelial activation.5 Collectively, these concurrent challenges indicate that ED may persist or even worsen during the post-TEVAR phase, thereby hindering optimal aortic remodeling and driving adverse clinical outcomes. EASIX, quantified the ED, is a novel biomarker gaining recognition for its prognostic utility. This study is the first to investigate the association between EASIX and TBAD after TEVAR. Our findings indicated that EASIX significantly influenced both short-term and long-term outcomes in patients with TBAD undergoing TEVAR, even after we adjusted for confounding risk factors. The prognostic utility of EASIX likely stems from the synergistic roles of its 3 components: LDH, creatinine, and PLT count. LDH reflects endothelial dysfunction19 and serves as a key marker of systemic inflammation.20 During inflammation and oxidative stress, LDH is released from endothelial cells, leukocytes, and PLT count, driving adverse vascular remodeling—a critical mechanism in AD progression.21,22 This aligns with evidence linking elevated LDH to increased in-hospital mortality in acute AD.23 Concurrently, vascular endothelial cell injury and dysfunction lead to the loss of regulatory function of renal endothelial cells, which have a detrimental impact upon renal function.24 One study indicated that impaired renal function, especially as calculated from creatinine levels at discharge, performed as a strong predictor of total mortality among patients with AD.25 This is consistent with our findings, in which patients in the greatest EASIX tertile exhibited a greater incidence of new-onset dialysis. Furthermore, reduced PLT levels may result from complement activation and endothelial damage. Endothelial damage exposes subendothelial collagen and elevates tissue factor and von Willebrand factor levels, triggering complement activation and consumptive platelet aggregation.26,27 Previous studies have shown that postoperative thrombocytopenia was an independent predictor of late all-cause mortality for patients with TBAD.28 Collectively, the synergistic integration of these 3 parameters comprehensively captures systemic inflammation, renal impairment, and coagulopathy, making EASIX a biologically plausible and reliable prognostic indicator. The baseline model constructed in this study incorporated statistically significant variables from multivariate analysis (excluding EASIX). Compared with this, superior AUCs were exhibited in the combined model (including EASIX) in both static and time-dependent ROC analyses. Numerous previous studies have identified age,29 maximum aortic diameter,30 anemia,31 WBC, and d-dimer index32 as risk factors for poor prognosis in AD. Our findings aligned with the conclusions of these studies, suggesting that EASIX may capture supplementary prognostic information independent of conventional parameters. As a low-cost adjunctive tool, EASIX supplements standard clinical evaluations to refine perioperative risk stratification and monitoring in patients with TEVAR. Our study highlights EASIX as a rapid and accessible tool for preoperative risk stratification that can be used to guide perioperative management. For patients with high preoperative EASIX scores, hydration to optimize renal clearance, strict blood pressure control, and minimized nephrotoxic exposure can be considered. Postoperatively, reassessment of EASIX components may facilitate early identification of complications such as organ ischemia or dialysis requirement, supporting prolonged intensive care unit or hospital monitoring when necessary. Given its strong association with long-term mortality, patients with a high-EASIX also warrant shorter follow-up intervals and intensive imaging surveillance. Furthermore, endothelial-protective agents—such as statins,33 anigotensin-converting enzyme inhibitors,34 and sodium-glucose cotransporter-2 inhibitors35—can be preferentially administered to patients with TBAD with relevant comorbidities to reduce oxidative stress. Ultimately, incorporating EASIX into routine practice allows for the allocation of medical resources to vulnerable populations. This study acknowledges several limitations. First, because the study was conducted at a single center in China and only enrolled patients with TBAD who were treated with TEVAR, selection bias and limited generalizability may exist. Second, the retrospective design may have introduced residual confounding factors (eg, residual malperfusion and immediate endoleak classification), despite efforts to adjust for potential confounders. Third, the relationship between EASIX and prognosis is associative rather than causal. Its clinical application warrants cautious interpretation and should be integrated into a comprehensive assessment of therapeutic strategies and patient management. Therefore, future prospective studies involving independent, multicenter cohorts are warranted to establish the robustness and broader clinical applicability of the EASIX. Nevertheless, our institution serves as a high-volume tertiary referral center for aortic diseases, and the large sample size of consecutive TEVAR procedures ensures a representativeness of the study population. In addition, the TEVAR surgical technique and perioperative management strategies were well-established and uniformly applied in our center. Therefore, our data and findings still carry considerable clinical relevance. In addition, the study underscores the clinical value of using routine laboratory parameters for prognostic information. EASIX can serve as an accessible, supplementary indicator for preoperative risk stratification, helping identify patients who are at high risk and guide tailored perioperative management. Furthermore, our study may stimulate investigation into the potential mechanisms underlying the association between EASIX and prognosis, as well as the development of targeted therapies. Conclusions EASIX was associated with both short-term and long-term outcomes in patients with TBAD undergoing TEVAR. Consequently, EASIX may represent a potential supplementary indicator that assists in preoperative risk stratification before intervention. Data Availability Provided there is a valid and reasonable request made for the information derived from this research, it can be obtained from the primary or corresponding author. Conflict of Interest Statement The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.